

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER POR PATENTS PO Box (430 Alexandra, Virginia 22313-1450 www.opto.gov

	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/509,333	04/05/2005	Grant William Vandenberg	P08911US01	1841	
22885 7590 12/10/2009 MCKEE, VOORHEES & SEASE, P.L.C. 801 GRAND AVENUE			EXAM	EXAMINER	
			MELLER, MICHAEL V		
SUITE 3200 DES MOINES, IA 50309-2721			ART UNIT	PAPER NUMBER	
			1655		
			Normal and Prince	DET HERMALORE	
			NOTIFICATION DATE 12/10/2009	DELIVERY MODE ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patatty@ipmvs.com

Application No. Applicant(s) 10/509,333 VANDENBERG, GRANT WILLIAM Office Action Summary Examiner Art Unit Michael V. Meller 1655 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 21 August 2009. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-32 is/are pending in the application. 4a) Of the above claim(s) 1-22 and 24-32 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 23 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.

1) Notice of References Cited (PTO-892)

Paper No(s)/Mail Date

Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (FTO/SB/08)

Attachment(s)

Interview Summary (PTO-413)
 Paper No(s)/Mail Date.

6) Other:

5) Notice of Informal Patent Application.

Application/Control Number: 10/509,333 Page 2

Art Unit: 1655

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Group IV, claim 23 and ground beans and deoxycholate only in the reply filed on 11/10/2008 is acknowledged. The traversal is on the ground(s) that all of the claims relate to a single unifying composition and various related uses thereof and as such do not require a separate search. This is not found persuasive because as noted on the record already the product is known, thus there is

no special technical feature and thus a lack of unity exists.

2. Newly submitted claims 25-32 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: the new claims, claim methods and compositions which lack unity of invention since they claim patentably distinct methods from the elected method and it has been shown already on the record that the claims lack unity of invention since the composition is known in the art

Thus, claims 1-22, 24-32 are withdrawn from further consideration as being drawn to non-elected subject matter.

The requirement is still deemed proper and is therefore made FINAL.

Application/Control Number: 10/509,333 Page 3

Art Unit: 1655

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all

obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was

made.

4. Claim 23 is rejected under 35 U.S.C. 103(a) as being unpatentable over Yamada

et al. in view of DE 19927963.

Yamada teaches that orally administered active substances can be made into tablets containing deoxycholate which is known for its dissolution capabilities, see col. 9. line 40-col. 10, line 15.

DE teaches that ground coffee beans can be made into tablets used for oral

application, see abstract.

It is well known that it is *prima facie* obvious to combine two or more ingredients each of which is taught by the prior art to be useful for the same purpose in order to Application/Control Number: 10/509,333

Art Unit: 1655

form a third composition which is useful for the same purpose. The idea for combining them flows logically from their having been used individually in the prior art. *In re Sussman,* 136 F.2d 715, 718, 58 USPQ 262, 264 (CCPA 1943); *In re Pinten,* 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); *In re Susi,* 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423, 426 (1971); *In re Crockett,* 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960). *In re Kerkhoven,* 626 F. 2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) (It is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition which is to be used for the very same purpose).

The reason or motivation to modify a reference may often suggest what the inventor has done, but for a different purpose or to solve a different problem. It is not necessary that the prior art suggest the combination to achieve the same advantage or result discovered by applicant. While there must be motivation to make the claimed invention, there is no requirement that the prior art provide the same reason as the applicant to make the claimed invention.

MPEP 2144 Sources of Rationale Supporting a Rejection Under 35 U.S.C. 103. http://www.uspto.gov/web/offices/pac/mpep/documents/2100 2144.htm>

Thus, since both ground beans and deoxycholate are both known individually in the art to be used for the same purpose, namely to be used in tablets which form an oral composition and since they clearly are administered to a human, then the claimed subject matter is obvious since all that the claims require is that the claimed invention be administered to a human. It is noted that in Yamada, a physiologically active substance is administered thus all claim limitations are met in the references.

Art Unit: 1655

Applicant argues that the references do not teach the claimed steps.

Applicant is reminded that the rejection is under 35 USC 103. Yamada clearly teaches administration to a human, see col. 9, lines 40-60, and DE teaches that the ground coffee bean tablets are easily handled and clearly imply to administer the tablet to a person. It is clearly obvious to administer the tablet to a person. A person receiving the combination of the two elected components (ground beans and deoxycholate) will inherently have an enhanced body uptake of the components and have a physiological reaction modulated since the same components as elected by applicant are being administered in the references as does applicant.

Double Patenting

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory

Application/Control Number: 10/509,333

Art Unit: 1655

obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Omum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3,73(b).

6. Claim 23 is provisionally rejected on the ground of nonstatutory double patenting over claim 21 of copending Application No. 11/676,349. This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

The subject matter claimed in the instant application is fully disclosed in the referenced copending application and would be covered by any patent granted on that copending application since the referenced copending application and the instant application are claiming common subject matter, as follows: the application claims the same subject matter.

Applicant has not filed a terminal disclaimer or arguments concerning this rejection thus the rejection is maintained. Application/Control Number: 10/509,333

Art Unit: 1655

7. Claim 23 is provisionally rejected on the ground of nonstatutory double patenting over claims 1-6, 8, 10, 12-18, 20, 29-31 of copending Application No. 10/181,428. This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

The subject matter claimed in the instant application is fully disclosed in the referenced copending application and would be covered by any patent granted on that copending application since the referenced copending application and the instant application are claiming common subject matter, as follows: the application claims the same subject matter.

Applicant has not filed a terminal disclaimer or arguments concerning this rejection thus the rejection is maintained.

8. Claim 23 is provisionally rejected on the ground of nonstatutory double patenting over claims 35-37 of copending Application No. 12/045,791. This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

The subject matter claimed in the instant application is fully disclosed in the referenced copending application and would be covered by any patent granted on that copending application since the referenced copending application and the instant application are claiming common subject matter, as follows: the application claims the same subject matter.

Art Unit: 1655

Applicant has not filed a terminal disclaimer or arguments concerning this rejection thus the rejection is maintained.

 THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael V. Meller whose telephone number is 571-272Art Unit: 1655

0967. The examiner can normally be reached on Monday thru Thursday: 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael V. Meller/ Primary Examiner, Art Unit 1655